Roche drug for rare blood disorder hits Phase 3 goals

The latest stories trending on MedCity News.

Editor's Pick

Top Story Roche Drug for Rare Blood Disorder Hits Phase 3 Goals; Regulatory Filings Are Next AstraZeneca dominates the market for drugs that treat rare blood disorder paroxysmal nocturnal hemoglobinuria. Roche drug crovalimab met the two main goals of its pivotal test, and if approved, would offer a dosing edge compared to AstraZeneca's two blockbuster PNH medicines.

Featured News

HLTH Foundation's Achievements and Ambitions for Health Equity HLTH Foundation Executive Director Janna Guinen described its focus on promoting equity, inclusion and opportunity in healthcare on behalf of patients, healthcare professionals and health tech entrepreneurs. Specialty Pharmacy Needs a Shake Up to Help the Chronically Ill For anyone suffering from a debilitating or life-threatening disease, the experience of procuring specialty medications […] Report: 88% Of Employers Are Planning Changes to Health Vendor Partnerships Employers are most interested in switching up their vendor partners for wellbeing programs, the Willis Towers Watson survey found. About 55% of respondents said they will make changes to their wellbeing vendor partners in 2023 or 2024, while 12% already did in 2022. Navina's Data Platform Slashes Administrative Burden Associated with VBC, Physicians Say Millennium Physician Group — an independent care group with more than 800 providers across Florida, Texas, and North Carolina — announced successful results following its adoption of Navina's AI platform. The organization said that the platform saved time, reduced burnout and gave physicians more confidence about forming care plans with patients. Blue Shield of California Adds Virta Health to Network for Diabetes Care Virta is available this month to all Blue Shield of California members enrolled in preferred provider organization plans for individual and family, fully insured, self funded and Medicare Advantage. The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California's Wellvolution, a platform of digital lifestyle apps. Why One VC Thinks Women's Health Is Poised to Take Off Soon Francesca de Quesada Covey, chief investment officer at investment firm TheVentureCity, believes the women's health sector will come into its own in the next few years. She said startups focused on improving care delivery will probably have the easiest time raising funds of all the companies in the femtech space.

Resources

AI in Healthcare: Scratching the Surface Learn how AI is transforming the healthcare industry and the pitfalls that also exist with its early adoption.   Download Now

MedCity News • 611 Broadway • New York, NY unsubscribe